231 results on '"Intlekofer, Andrew M"'
Search Results
2. Retrospective characterization of nodal marginal zone lymphoma
3. TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
4. FXR mediates T cell-intrinsic responses to reduced feeding during infection
5. In vivo library screening identifies the metabolic enzyme aldolase A as a promoter of metastatic lung colonization
6. Specific patterns of H3K79 methylation influence genetic interaction of oncogenes in AML
7. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
8. CD8+ T cell metabolic flexibility elicited by CD28-ARS2 axis-driven alternative splicing of PKM supports antitumor immunity
9. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis
10. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
11. TP53mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
12. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting
13. JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
14. D-2HG comes out of its shell: Metabolic effects on the immune environment
15. Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay
16. Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
17. Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing
18. Characterization of a Large Cohort of Patients with Nodal Marginal Zone Lymphoma Shows Prolonged Survival, Time-to-Treatment, and Time-to-Transformation
19. Mitonuclear genotype remodels the metabolic and microenvironmental landscape of Hürthle cell carcinoma
20. Anomalous Type 17 Response to Viral Infection by CD8⁺ T Cells Lacking T-Bet and Eomesodermin
21. Asymmetric T Lymphocyte Division in the Initiation of Adaptive Immune Responses
22. A Role for the Transcriptional Repressor Blimp-1 in CD8+ T Cell Exhaustion during Chronic Viral Infection
23. T cells critically depend on pyruvate oxidation
24. Favorable Outcomes Among Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with Higher-Intensity Therapy in the Rituximab Era
25. Distinct Patterns of CD4+ and CD8+ T-Cell Clonal Expansion Enable Broad Clinical Responses to Pembrolizumab + GVD in Patients with Relapsed Hodgkin Lymphoma
26. Infectious Complications in Patients with Relapsed or Refractory (R/R) Non-Hodgkin's Lymphoma (NHL) Treated with the Anti-CD20xCD3 Bispecific Antibody (BsAb) Mosunetuzumab
27. Predicting Toxicities in Older Adults with Non-Hodgkin Lymphoma (NHL) Receiving Systemic Chemotherapy: A Prospective Geriatric Assessment (GA) Study
28. Clinical Characteristics and Outcomes of Limited Stage High Grade B-Cell Lymphoma with MYC/BCL2 and/or BCL6 Rearrangements: A Single Center Experience
29. Brentuximab Vedotin-Based Regimens for Older Patients with Newly Diagnosed Classical Hodgkin Lymphoma -Real World Experience
30. Impact of Early Histological Transformation on Survival in Patients with Follicular Lymphoma
31. A Phase 1b Multi-Center Study of the FLT3 Inhibitor Gilteritinib in Combination with the IDH1 Inhibitor Ivosidenib or the IDH2 Inhibitor Enasidenib for Patients with Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring FLT3/IDH1 or FLT3/IDH2 Mutations
32. Responses and Outcomes after Second-Line Therapy in Transplant-Eligible Patients with DLBCL Relapse over 1 Year after First-Line Therapy
33. Real-Life Experience with Lenalidomide Plus Anti-CD20 Antibodies for the Treatment of Patients (pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
34. In vivo library screening identifies the metabolic enzyme aldolase A as a promoter of metastatic lung colonization
35. Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
36. Nitrogen Trapping as a Therapeutic Strategy in Tumors with Mitochondrial Dysfunction
37. Oncogenic Mechanisms and Therapeutic Targeting of Metabolism in Leukemia and Lymphoma
38. As Extracellular Glutamine Levels Decline, Asparagine Becomes an Essential Amino Acid
39. High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma
40. Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
41. JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
42. Pre-TCR signaling inactivates Notch1 transcription by antagonizing E2A
43. Hypoxia Induces Production of L-2-Hydroxyglutarate
44. T-bet represses expression of PD-1 and sustains virus-specific CD8 T cell responses during chronic infection
45. Outcomes of Follicular Lymphoma Patients By Dynamic FLIPI at Diagnosis and Initial Treatment in the Post-Rituximab Era
46. Intervention Versus Observation: What Is the Appropriate Endpoint? Assessment of Endpoints in Patients with Advanced Stage Follicular Lymphoma Who Are Initially Observed
47. Benchmark of Progression Free Survival for Multiple Lines of Therapy in Follicular Lymphoma Treated in the Rituximab Era
48. Lymphoproliferation Caused by Fas Deficiency Is Dependent on the Transcription Factor Eomesodermin
49. Comprehensive Genomic Profiling (CGP) of Angioimmunoblastic T-Cell Lymphoma (AITL) to Prospectively Inform Diagnosis and Clinical Management
50. Distinctive Genomic Alterations in Testicular Diffuse Large B Cell Lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.